Product Name:
DNM2-pS764
Product Number:
ab-pn950
Target Full Name: Dynamin-2
Target Alias: CMTDI1; CMTDIB; Cytoskeletal protein; DI-CMTB; Dynamin 2; Dynamin II; DYNII
Product Type Specific: DNM2 phosphosite-specific antibody
Antibody Code: PN950
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S764
Protein UniProt: P50570
Protein SigNET: DNM2
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Synthetic phosphopeptide patterned after human DNM2
Antibody Immunogen Sequence: CASSH(pS)PTP
Antibody Immunogen Description: Corresponds to amino acid residues A670 to P767. S764 phosphorylation regulates intracellular location and protein interactions. This is one of the major in vivo phosphorylation sites in DNM2 with ≥8 mass spectrometry reports recorded in PhosphoSitePlus. DNM2 is known to be phosphorylated at this site in vitro by CDK1, and CDK2.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.35 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Rhesus macaque | Dog | Rat | Mouse.
Related Product 1: DNM2 Y597 phosphorylation antibody (Cat. No.: AB-PN951)
Scientific Background: DNM2 (Dynamin-2; DYN2) is a hydrolase that belongs to the TRAFAC class dynamin-like GTPase superfamily, Dynamin/Fzo/YdjA family. It features an N-terminal GTPase domain, a pleckstrin homology (PH) domain that binds to the membrane, and a proline-arginine-rich domain (PRD) that interacts with other proteins. It functions as a microtubule-associated force-producing protein involved in producing microtubule bundles. It catalyzes the hydrolysis of GTP and utilizes this energy to mediate vesicle scission at plasma membrane during endocytosis and filament remodeling at many actin structures during organization of the actin cytoskeleton. It plays an important role in vesicular trafficking processes, namely clathrin-mediated endocytosis (CME), exocytic and clathrin-coated vesicle from the trans-Golgi network, and PDGF stimulated macropinocytosis. It participates in the regulation of neuron morphology, axon growth and formation of neuronal growth cones. It has an important role in vesicular trafficking processes, in particular endocytosis. It is involved in cytokinesis. It regulates maturation of apoptotic cell corpse-containing phagosomes by recruiting PIK3C3 to the phagosome membrane. In Centronuclear Myopathy (CNM) many mutations that lead to a "gain-of-function," disrupt muscle cell structure, specifically the transverse tubules (T-tubules) necessary for contraction. Other mutations may cause the peripheral nerve disorder Charcot-Marie-Tooth (CMT) Neuropathy. Overexpression of DNM2 has also been implicated in cancer cell migration, invasion, and tumour progression. This description may include information annotated by UniProt and/or Google AI.

